Zealand Pharma CEO on weight loss data: We couldn't have hoped for more

New results from the company’s petrelintide weight loss drug were at the top of the expected range.
Adam Steensberg, CEO, Zealand Pharma. | Photo: Stine Bidstrup
Adam Steensberg, CEO, Zealand Pharma. | Photo: Stine Bidstrup
by SOFIE HØJLUND, MARKETWIRE ‎

”Crazy good data”. This is how Adam Steensberg, CEO of Zealand Pharma, describes the long-awaited preliminary results from a Phase Ib study of the company’s obesity drug candidate petrelintide.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Further reading